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Abstract
Acute kidney injury (AKI) is defined as an abrupt decrease in glomerular filtration rate 
(GFR). Incidence varies from 20% to as high as 70% in critically ill patients. Classically, 
AKI has been divided into three broad pathophysiologic categories: prerenal AKI, intrin-
sic AKI, and postrenal (obstructive) AKI. The clinical manifestations of AKI vary among 
a wide range of symptoms and metabolic abnormalities. A sudden decrease in GFR will 
result in rising concentrations of solutes in the blood, which are normally excreted by 
the kidneys. Recently, new urinary and serum biomarkers have gained a place in the 
diagnosis, classification, and prognosis prediction of AKI. The best treatment for AKI 
is prevention. Patients with prerenal azotemia should have intravascular volume defi-
cits corrected and cardiac function optimized. Obstructive (postrenal) kidney disease is 
treated by mechanical relief of the block. The primary management of acute interstitial 
nephritis is discontinuation of the inciting agent. Renal replacement therapy (RRT) has 
emerged as a supportive mechanism rather than just as a lifesaving measure. Continuous 
techniques are preferable in treating critically ill patients, although every modality has its 
benefits, indications, and contraindications.
Keywords: acute kidney injury, acute renal failure, intensive care unit, glomerular 
filtration rate, renal replacement therapy
1. Introduction
Acute kidney injury (AKI) is now recognized as a major health problem that affects millions 
of patients worldwide and leads to decreased survival and increased risk of progression to 
chronic kidney disease (CKD). It is often diagnosed along with other acute illnesses and is 
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common in critically ill patients. AKI has also an important role since it is strongly associated 
with augmented costs of care, worse outcomes, and diminished quality of life after discharge. 
The impact and prognosis of AKI vary considerably depending on the severity, clinical set-
ting, comorbid factors, and geographical location [1].
AKI in the ICU is common, and it is increasing in incidence. Reported mortality in ICU 
patients with AKI varies between studies depending on AKI definition and the patient popu-
lation studied. In most studies, mortality increases proportionately with increasing severity 
of AKI. In patients with severe AKI requiring renal replacement therapy (RRT), mortality is 
approximately 50–70%. Although AKI requiring RRT in the ICU is a well-recognized inde-
pendent risk factor for in-hospital mortality, even small changes in serum creatinine (SCr) are 
associated with increased mortality.
The definition of AKI has many perceptions, the simplest way to describe it is as a sudden 
decrease in glomerular filtration rate (GFR) resulting in the retention of metabolic waste prod-
ucts and the dysregulation of fluid, electrolyte and acid-base homeostasis. AKI is a hetero-
geneous syndrome that includes hemodynamic disarrangements that disturb normal renal 
perfusion and decrease GFR without overt parenchymal injury; partial or complete obstruc-
tion to urine flow; and acute parenchymal injury resulting in glomerular, interstitial, tubular, 
or vascular dysfunction. The most common causes of AKI in critically ill patients include 
hemodynamically mediated prerenal dysfunction and acute tubular necrosis (ATN) due to 
ischemia-reperfusion injury, nephrotoxic exposure, or sepsis [2].
The cardinal manifestation of AKI is the retention of metabolic waste products, most com-
monly represented by creatinine and urea, and/or fluid accumulation. More than 35 clini-
cal definitions of AKI currently exist in the literature. The Acute Dialysis Quality Initiative 
convened in 2002 and proposed the RIFLE classification (risk, injury, failure, loss, end-stage 
kidney disease) specifically for AKI in critically ill patients. Using SCr and urine output, 
the RIFLE criteria define three grades of severity and two outcome classes. Later, the Acute 
Kidney Injury Network (AKIN) proposed another clinical and practical definition. Even 
small changes in serum creatinine concentrations are associated with a substantial increase 
in the risk of death. For this reason, in 2012, the Kidney Disease Improving Global Outcomes 
(KDIGO) classification defined AKI as a raise of serum creatinine of at least 0.3 mg/dl or as a 
urine output of less than 0.3 ml/kg/h for at least 6 h (Table 1) [3].
2. Epidemiology
The epidemiology of AKI varies depending on the type and characteristics of the population 
described. Using the current 0.3-mg/dl change in serum creatinine threshold, published data 
ranges the incidence of AKI in hospitalized patients from 3 to 50% and from 10 to 70% in 
the intensive care unit (ICU). A 2013 meta-analysis of AKI incidence per the kidney improv-
ing global outcomes staging system with a total number of patients included of 3,585,911, 
reported incidence in 23% overall hospitalized patients [4].
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Among critically ill patients, numerous cohort studies have been issued to define the incidence 
of AKI in ICU. Final reports suggest that it goes as high as 70% in some populations. Patients 
with ICU-associated AKI are younger, more likely to be male and prone to have AKI associ-
ated with multisystem organ failure as opposed to isolated AKI. The most important recog-
nized risk factor for AKI in the ICU environment is sepsis. Other important risk factors include 
previous diagnosis of Diabetes, Hypertension or CKD, concomitant use of vasopressors and 
use of mechanical ventilation. Renal replacement therapy (RRT) rates and mortality associated 
to AKI are significantly higher among ICU population opposed to hospitalized patients [5].
Two distinct patterns of ICU-associated AKI have been described: community-acquired AKI, 
present at ICU admission, and hospital-acquired AKI. Patients with hospital-acquired AKI 
have more severe outcomes, showing higher in-hospital mortality rates, longer lengths of stay 
both in the ICU and hospital, and higher needs of RRT [6, 7].
3. Pathophysiology
AKI can be divided into three broad etiologic categories: prerenal AKI, intrinsic AKI, and 
postrenal (Figure 1). Prerenal refers to states of hypoperfusion of the kidneys without a 
parenchymal damage, this kind of AKI occurs often in ICU patients. Postrenal or obstruc-
tive AKI is characterized by acute block of the urinary tract. Regarding intrinsic dysfunction, 
acute damage to the renal parenchyma exists, as in acute tubular necrosis, acute interstitial 
nephritis and/or acute glomerular nephritis. The terms “prerenal,” “intrinsic,” and “postre-
nal” are used to group common pathophysiologic features and not diagnosis. It was a long-
held view that “prerenal AKI” or “transient” AKI were synonymous with “hypovolemic AKI” 
and “fluid responsiveness,” this is no longer the case and must not be used in this manner. 
Approach to the diagnosis and treatment is described below [8, 9].
Stage RIFLE AKIN KDIGO Urine output
RIFLE–Risk AKIN/
KDIGO Stage 1
Increase in serum 
creatinine × 1.5 
(within 7 days)
Increase in serum 
creatinine of 0.3 mg/
dl or > × 1.5 (within 
48 h)
Increase in serum 
creatinine of 0.3 mg/
dl (within 48 h) or × 
1.5 (within 7 days)
Urine output of  




Increase in serum 
creatinine × 2
Increase in serum 
creatinine × 2
Increase in serum 
creatinine × 2
Urine output of  




Increase in serum 
creatinine × 3 or 
above 4.0 mg/dl
Increase in serum 
creatinine × 3 or 
above 4.0 mg/dl
Increase in serum 
creatinine × 3 or 
above 4.0 mg/dl
Urine output of  
< 0.3 mg/kg/h for > 24 
h or anuria for > 12 h
RIFLE–Loss Need for RRT for >4 
weeks
RIFLE–End stage Need for RRT for >3 
months
Table 1. AKI definition by clinical parameters per RIFLE, AKIN, and KDIGO.




Prerenal AKI is the most common pathophysiologic cause of AKI, contributing to the devel-
opment 30–60% of all cases of AKI in ICU. Prerenal AKI develops when the capacity of the 
normal physiologic responses to hypovolemia is exceeded. This response initiates with a 
decrease in mean arterial pressure, triggering baroreceptors that lead the activation of the 
sympathetic nervous system, activation of the renin-angiotensin-aldosterone system (RAAS), 
and secretion of the antidiuretic hormone vasopressin. The activation of the renal sympa-
thetic nerves constricts the afferent (preglomerular) arterioles and stimulates release of renin 
from the juxtaglomerular apparatus. Renin secretion is also directly stimulated in response to 
hypovolemia by changes in intrarenal hemodynamic. Secretion of renin activates a cascade 
with the final production of angiotensin II. Angiotensin II stimulates both afferent and effer-
ent (postglomerular) arteriolar vasoconstriction; however, the effect on the afferent vessel is 
opposed by vasodilatory prostaglandins, kallikrein, kinins, and nitric oxide. The net effect 
is vasoconstriction of both afferent and efferent arterioles and decrease of GFR to maintain 
circulating volume at near normal levels by the production of concentrated urine with low 
sodium content (i.e., fractional excretion of sodium) [10–12].
In classic forms of prerenal AKI, reduced renal perfusion pressure (or increased renal venous 
pressure) and afferent arteriolar constriction combined lower the glomerular capillary hydro-
static pressure below the autoregulation capacity and consequently the net ultrafiltration 
pressure, hence diminishing GFR. Prerenal AKI may be caused by extracellular fluid volume 
loss or shifts, reduced cardiac output, systemic vasodilation, intrarenal vasoconstriction, or 
increased renal venous pressure.
Figure 1. Traditional etiologic categories for AKI.
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3.2. Renal AKI
Intrinsic AKI is commonly divided into tubular, interstitial, glomerular, and vascular pro-
cesses depending on the nephron region that is the most affected. The most common intrinsic 
cause of AKI is ATN, accounting for 85–90% of intrinsic ICU-associated AKI. The causes of 
ATN can be broken down into three major categories: ischemia-reperfusion injury, nephro-
toxic, and septic. Sepsis-associated ATN has unique features and may develop in the absence 
of overt renal ischemia [13].
3.2.1. Sepsis-associated ATN
Sepsis has long been recognized as a foremost precipitant of AKI and deserves a distinc-
tion. Sepsis-associated AKI (SA-AKI) portends a high burden of morbidity and mortality in 
both children and adults with critical illness. Observational data suggest that injury during 
SA-AKI occurs early of the critical illness and after ICU admission. In a large recent cohort, 
68% of 5443 patients with septic shock had evidence of AKI within 6 h after presentation. The 
development of AKI later during an episode of sepsis has been associated with worse clinical 
outcome and increased mortality rates (76.5 vs. 61.5% in early AKI) [14].
Sepsis-mediated hypo perfusion leading to tubular necrosis has been traditionally cited as the 
main pathophysiology for SA-AKI; however, mounting evidence has challenged this para-
digm. Numerous drivers for injury now are recognized as playing a role in SA-AKI, including 
ischemia-reperfusion injury, nephron inflammation, hypoxic and/or oxidant stress, cytokine 
and chemokine-driven direct tubular injury, and tubular and mesenchymal apoptosis. For 
instance, renal vein thermodilution measurement of RBF in eight septic critically ill patients 
did not show hypoperfusion to the glomerulus consistently. Tubular cellular injury contributes 
to the propagation of AKI during sepsis. Several causal mechanisms appear to be involved, but 
tubular necrosis, traditionally cited as the major cellular switch for injury, is not supported by 
the available experimental evidence. Renal tubular apoptosis in response to the stress of sys-
temic sepsis now is cited as a potential contributing mechanism of injury in SA-AKI [14–16].
Similarly, cellular hypoxia is a molecular driver of injury during SA-AKI. Tissue hypoxia 
in the kidney during sepsis may be defined by inflammation, changes in intrarenal nitric 
oxide, nitrosative stress or oxygen radical homeostasis, and dysregulation. Downregulation 
of mediators of oxidative phosphorylation occurs during sepsis and protection of mitochon-
drial respiration may mitigate renal injury during sepsis [14, 17, 18].
3.3. Postrenal AKI
AKI resulting from obstruction usually causes fewer than 5% of ICU-associated AKI. Obstruction 
above the level of the bladder is referred to as upper tract obstruction. The development of 
AKI from upper tract obstruction requires the presence of bilateral obstruction or unilateral 
obstruction in the setting of a single functioning kidney or dysfunction of the contralateral 
kidney.
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Patients with obstructive disease may present with anuria if obstruction is complete, with 
normal or increased urine volume in a partial obstruction, or with fluctuating urine output 
with periods of anuria alternating with rapid passage of urine as the pressure in the collecting 
system rises and overcomes the block. In the acute phase of obstruction, intratubular pressure 
rises over venous renal pressure replacing the latter in the net filtration pressure equation. 
When intratubular pressure reaches close to mean arterial pressure, net filtration pressure 
falls below the autoregulation range, sometimes almost to zero [19].
4. Clinical findings
The clinical manifestations of AKI vary from a wide range of signs and symptoms. The syn-
drome encompasses from laboratory abnormalities without symptoms to organ failure exhib-
iting fluid overload and severe electrolyte and/or acid-base disturbances [20].
A sudden decrease in GFR results in rising concentrations of waste products, commonly 
represented by urea end creatinine in the blood. The relationship between the GFR and the 
concentration of urea and creatinine in blood stream is nonlinear and may be affected by 
a variety of other factors. The level of blood urea nitrogen (BUN) generally correlates with 
the symptoms, with uremic manifestations usually absent until the BUN is above 100 mg/dl. 
Creatinine is derived from the nonenzymatic hydrolysis of creatine, which is usually released 
at a constant rate from skeletal muscle and is excreted primarily by filtration at the glomeru-
lus. There is essentially no tubular reabsorption of creatinine. That is why, in the absence of 
glomerular filtration, serum creatinine typically increases by 1–2 mg/dl/day. The role of cre-
atinine as a marker of renal function is limited by the fact that the serum concentration may 
take 24–36 h to rise after a renal insult. Additionally, ICU patients commonly accumulate fluid 
due to intravenous administration and concomitant AKI. Fluid overload decreases creatinine 
concentration since it dilutes the total amount of creatinine in the extracellular fluid. A true 
change in GFR may not be adequately reflected by serum creatinine in patients with sepsis, 
liver disease, fluid overload, and/or muscle wasting [20].
Urine output of less than 400–500 ml/day or a sustained urine output of less than 20 ml/h in a 
high-risk patient in the absence of volume depletion almost always indicates the presence of 
AKI. By KDIGO definition, a urine output of less than 0.5 ml/kg/h for 6 h indicates the occur-
rence of AKI [3].
4.1. Biomarkers
Cystatin C is a cysteine protease inhibitor that is released into the bloodstream at a constant 
rate from all nucleated cells. It is filtered at the glomerulus and reabsorbed and catabolized by 
renal proximal tubular epithelial cells such that virtually no cystatin C appears in the urine. 
The interindividual variability in cystatin C production appears to be less than that for creati-
nine. Cystatin C may be a more reliable marker of GFR [21].
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Several relatively new biomarkers of tubular injury have been proposed as novel diagnostic 
tests for the early diagnosis of AKI. These markers include kidney injury molecule-1 (KIM-1), 
neutrophil gelatinase-associated lipocalin (NGAL), interleukin 18 (IL-18), liver fatty acid bind-
ing protein (L-FABP), and α- and π-glutathione-S-transferase (GST), among others. They have 
been tested particularly amid cardiac surgery patients, with good predicting values. Even 
though these markers seem promising, these are not suitable for indiscriminate use in every 
ICU patient, and their exact specific role at the bedside remains uncertain [22, 23].
A novel test method measures two small tubular cell–derived molecules, Insulin-like Growth 
Factor Binding Protein 7 (IGFBP7) and Tissue Inhibitor of Metalloproteinase 2 (TIMP-2). 
IGFBP7 and TIMP-2 are markers of cell cycle arrest and possibly apoptosis, inflammation, and 
tubular cell repair. The above-stated conditions appear to be the most relevant in the devel-
opment of tubular cell injury, when the loss of cell polarity, brush border derangement, and 
cell sloughing might occur. Such injury may deflect the organism from normal repair toward 
maladaptive and lead to CKD, which further predisposes the individual to recurrent AKI [24].
According to recently published data, this test possesses the highest sensitivity for detecting 
AKI at an early stage. The Astute140™ meter is a device based on a fluorescence labeling tech-
nique, which detects fluorescent signals from the immunoassay and calculates concentrations 
of IGFBP7 and TIMP-2 from the inserted cartridge. The device converts the measured signals 
into a single number, defining the relative risk of the patient developing AKI. The result, 
known as the AKIRisk score, is obtained within 20 min [25].
5. Approach
The first step in evaluating a patient with AKI in the ICU is to determine whether kidney hypo 
perfusion plays a role in the current state. Physical examination should focus on assessing for 
evidence of volume depletion, such as dry mucous membranes, decreased skin turgor, and 
absence of sweat in the axilla and inguinal regions. If necessary, a more complete assessment 
should be done before or at the ICU. Advance hemodynamic monitoring is reasonable in 
high-risk patients, particularly using dynamic measurements of cardiac function, or even a 
complete ultrasound and echocardiographic evaluation at the bedside [26].
Placement of a bladder catheter should be performed to exclude urethra obstruction as a 
cause of AKI, but primarily, to initiate real-time urinary flow monitoring. Urinary output 
express information of whether our actions and treatment result in the patients’ improve-
ment. Urinary sediment should be examined under the microscope to discard other causes of 
AKI, especially intrinsic causes. In the presence of proteinuria, a urinary sediment contain-
ing abundant cells or casts suggests an intrinsic cause of AKI rather than hypoperfusion as 
the primary mechanism. Precisely, the presence of renal tubular epithelial cells, epithelial 
cell casts, or pigmented (muddy brown) granular casts suggests the diagnosis of ATN and 
is associated with the increased risk for bad outcomes. A normal urine sediment suggests 
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the presence of either a prerenal or postrenal pathophysiology of AKI, although obstructive 
uropathy may be associated with haematuria, pyuria, or crystalluria. The electrolyte compo-
sition of the urine may be helpful in differentiating between prerenal and ATN (i.e., fractional 
excretion of sodium), but not to guide the treatment [27, 28].
Imaging of the kidneys and bladder is required for the diagnosis of obstructive kidney disease 
and might provide information about the prehospital kidney function. Enlarged kidneys in 
a diabetic patient suggest that a previous damage was present, and GFR was diminished at 
baseline. This is especially helpful in a community-acquired AKI patient in whose previous 
renal function is unknown.
5.1. Clinical vs. subclinical AKI
The pitfalls of currently recommended diagnosis of AKI (i.e. creatinine and urinary flow) 
and the discovery of the above-mentioned new biomarkers have created new insights in AKI 
approach. The alteration of tubular and cellular arrest biomarkers, without creatinine eleva-
tion or a diminish of urinary flow, has led to the theory that at least some of the nephrons in 
the kidneys have suffered damage despite lack of azotemia (i.e. subclinical AKI). New clas-
sification for AKI has been proposed based on this. This new classification encompasses both 
clinical (i.e., with elevation in creatinine) and subclinical (i.e., alteration in biomarkers without 
creatinine elevation) AKI (Figure 2) [3, 23].
6. Treatment
The best treatment for AKI is acknowledging the existing risk factors and prevention. Diminish 
the time of hypo perfusion in every patient with AKI by a rapid recognition of cardiac output 
deficits, keeping an adequate intravascular effective volume and avoid nephrotoxic are key-
stones of prevention.
There is no specific management that accommodates the clear majority of patients with estab-
lished AKI. Patients with prerenal AKI, as mentioned, should have intravascular volume 
deficits corrected and cardiac function optimized. Obstructive (postrenal) kidney disease is 
treated by mechanical relief of the obstruction. The primary management of acute interstitial 
Figure 2. Clinical vs. subclinical AKI.
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nephritis is discontinuation of the inciting agent; in patients with persistent AKI, there may be 
a role for treatment with glucocorticoids.
Once volume status and cardiac output have been optimized, if the patient remains oli-
guric, the use of a unique trial of diuretics to establish urine output can be considered. 
Although nonoliguric forms of ATN are associated with significantly lower risk of morbid-
ity and mortality than oliguric forms, the primary rationale for a trial of diuretic therapy is 
to facilitate volume management not to improve AKI. None of the most common diuretics 
used in ICU worldwide increase the GFR. Positive fluid balance after development of AKI is 
associated with increased mortality rate, and avoiding fluid accumulation has a protective 
effect over mortality. The use of renal vasodilators, including dopamine, fenoldopam, and 
atrial natriuretic peptide, has not been shown to be beneficial in AKI, and its use should be 
discouraged [3].
AKI is associated with the development of sometimes serious electrolyte and acid-base dis-
turbances, including hyperkalemia, hyponatremia, hyperphosphatemia, hypo- and (less 
commonly) hypercalcemia, hypermagnesemia, hyperuricemia, and metabolic acidosis. In 
addition, AKI is associated with anemia, bleeding diatheses, increased risk of infections, and 
dysfunction of other organ systems, including cardiovascular dysfunction, respiratory fail-
ure, gastrointestinal complications, and neurologic disturbances. These complications should 
be in mind of the treating physician in the ICU at every time [29, 30].
6.1. Renal replacement therapy
In patients with severe AKI, RRT is the cornerstone of supportive management. One objec-
tive of RRT includes allowing the removal of fluid and solutes that accumulate during renal 
failure. The available modalities of RRT comprise intermittent hemodialysis (IHD), the vari-
ous forms of continuous renal replacement therapy (CRRT), and the hybrid modalities of 
prolonged intermittent RRT (PIRRT; also, extended duration dialysis [EDD] or sustained low-
efficiency dialysis [SLED]) [31, 32].
Solute removal during RRT may occur by diffusion down a concentration gradient from the 
blood across a semipermeable membrane into dialysate or by convective transport of solute 
across the membrane during filtration. Fluid removal occurs by filtration, driven by either a 
hydrostatic or osmotic pressure gradient across the semipermeable membrane. In conven-
tional IHD, the patient’s blood passes through a semipermeable hemodialyzer counter current 
to the flow of dialysate on the other side of the membrane. The dialysis solution has a composi-
tion that approximates the normal electrolyte conformation of extracellular fluids and creates 
equilibrium to the blood, normalizing solutes. CRRT utilizes either diffusive hemodialysis, 
convective hemofiltration, or a combination of both. In addition to the duration of therapy, 
the major difference between intermittent and continuous hemodialysis is the dialysate flow 
rate. In intermittent hemodialysis, dialysate flow rates (typically 500–800 ml/min) are equal to 
or greater than blood flow rates, allowing rapid solute clearance. In continuous hemodialysis, 
the dialysate flow rate (typically 15–30 ml/min) is slow compared to that of the blood, permit-
ting virtual equilibration of low-molecular-weight solutes such as urea between the blood and 
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dialysate. Thus, solute clearance for low-molecular-weight solutes approximates the dialysate 
flow rate. Nonetheless, the total daily or weekly clearance is greater with continuous treat-
ment, due to the extended time of therapy.
In continuous hemofiltration, a high filtration rate is generated, and physiologic replacement 
fluid is administered at an equal rate. Negative fluid balance (ultrafiltration) is accomplished 
by administering less milliliter per hour (usually 50–400 ml/h). Solute removal occurs exclu-
sively by convection, and clearance is approximately equal to the ultrafiltration rate. The 
convective transport is limited primarily by the pore size of the membrane, so hemofiltra-
tion provides more efficient clearance of higher molecular weight (>500–15,000 KDa) solutes. 
Although it has been proposed that removal of higher molecular weight solutes with hemofil-
tration as compared to hemodialysis would be of clinical benefit, this has not been borne out 
in clinical trials. Because of their prolonged duration, the net ultrafiltration rate required to 
attain the same daily fluid removal is lower with CRRT than with IHD. Thus, CRRT is gener-
ally considered to cause less hemodynamic instability than conventional IHD [33].
Finally, PIRRT is a modification of conventional IHD, utilizing lower blood and dialysate flow 
rates while prolonging the treatment duration to 8–16 h.
There has been considerable debate regarding which modality is most appropriate for use in 
critically ill patients with AKI. Current data suggest that no individual modality of RRT pro-
vides either better patient survival or recovery of kidney function. These modalities should 
be complementary and must not be considered as mutually exclusive. According to the 
KDIGO guidelines, CRRT must be considered the first-line treatment in hemodynamically 
unstable patients and those with neurological illness whom require RRT and might be prone 
to develop cerebral edema [3].
Conventional indications for initiation of RRT include volume overload unresponsive to 
diuretic therapy, electrolyte and acid-base disturbances refractory to medical management, 
severe hyperkalemia, metabolic acidosis, overt uremia, characterized pericarditis, or encepha-
lopathy. Most of the AKI patients in the ICU do not spent enough time in the hospital to 
express most of these indications. Initiating RRT in a patient with some of the conventional 
indications is unquestionable, although the use in other cases when the alterations do not 
endanger life immediately is uncertain. Studies have shown conflictive results when compar-
ing the so-called early and late initiation strategies, with no clear benefit from one over the 
other. Even, there is no definition of either of them. Benefits of connecting a specific patient 
should be opposed to the risks of the same action, and each case should be individualized. 
Keep in mind, the potential harms of connecting too early include unnecessary exposure to 
the risks related to the catheter insertion, diminishing intravascular effective volume (espe-
cially in IHD), and resources utilization that increase costs. The unwanted adverse effect of 
taking too long in initiating might be death [34].
7. Outcomes
The mortality rate increases with AKI, independently associated to the underlying disease and 
baseline characteristics. Much higher mortality rates are associated with intrinsic forms of AKI over 
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prerenal or postrenal disease. In severe septic-related AKI, short-term mortality rates approach 
50–70% and have changed little over the past three decades. Factors associated to increased mor-
tality risk include sepsis, male gender, advanced age, the use of RRT, degree of creatinine increase 
and coexistent nonrenal organ failure. For those patients who survive, AKI is associated with 
prolonged length of hospitalization and substantial health resource utilization [35].
More than half of patients who recover their renal function can be demonstrated to have 
subclinical kidney disease including modest decrements in GFR, diminished renal functional 
reserve, defects in tubular function and urinary concentration, and tubule-interstitial scarring 
on kidney biopsy [36].
8. Conclusions
AKI in hospitalized patients is a contributing factor for poor prognosis and outcomes. In criti-
cally ill patients, AKI etiologies differ, but the core one is the occurrence of renal hypo perfu-
sion during shock states. Therefore, the best treatment of AKI is prevention. Additionally, 
hemodynamic optimization and diminishing offending factors are also crucial. Several 
modalities for RRT are available, and they should be considered complimentary. The ideal 
initiation timing depends on every patient’s needs and benefits should be opposed to risk 
continuously during each patient’s evolution.
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